These studies suggest an encouraging potential for Mas agonism as a neuroprotective treatment following ischaemic stroke, however the majority of promising results were obtained with intracerebral delivery of Ang-(1–7) (Table 1) with just one study using a more translationally relevant approach through oral administration [250]. Here, ANG is linked to ischemic stroke.